Status
Conditions
About
This is a prospective, multi-center clinical study of Multi-Cancer Early Detection (MCED) testing in cancer patients and healthy volunteers. The purpose of this study is to establish MCED platform through the analysis of whole genome sequencing of circulating DNA.
The study will enroll 4,000 subjects as defined by eligibility criteria at up to 10 clinical institutions in South Korea.
Full description
AIMA is analysing whole genome sequencing data of circulating tumor DNA, combined through machine learning technique, to develop MCED platform to detect early stage cancer.
The purpose of this prospective, multi-center, observational study is to validate an MCED platform for the early detection of cancers.
The investigators will collect blood samples from subjects who are diagnosed as invasive cancers before treatment or from healthy volunteers.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
4,000 participants in 2 patient groups
Loading...
Central trial contact
Joohyuk Sohn
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal